Get started
Author

Jaiqi Huang

OpenAlex ID: A5010972126
Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors
2014 · Paul Haluska, Michael Menefee, et al. · Clinical Cancer Research · 64
Data Supplement from Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors
2023 · Paul Haluska, Michael Menefee, et al.
Data Supplement from Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors
2023 · Paul Haluska, Michael Menefee, et al.
Data Supplement from Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors
2023 · Paul Haluska, Michael Menefee, et al.
Data Supplement from Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors
2023 · Paul Haluska, Michael Menefee, et al.
Data from Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors
2023 · Paul Haluska, Michael Menefee, et al.
Data from Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors
2023 · Paul Haluska, Michael Menefee, et al.
Works count: 7
Citation count: 64
H-index: 1
I10-index: 1
Year
Topic
Type